TruDiagnosis System
May 2019
156d
Akonni Biosystems, Inc. has submitted 1 FDA 510(k) premarket notifications since 2019, of which 1 received clearance as substantially equivalent to a predicate device.
The company's most frequent device categories include Cytochrome P450 2c9 (cyp450 2c9) Drug Metabolizing Enzyme Genotyping System . Use the specialty filter in the sidebar to narrow results.